- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00528827
A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension
March 15, 2012 updated by: Facet Biotech
To define the relationship between Cardene I.V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.
Study Overview
Detailed Description
Children with acute hypertensive episodes are frequently treated with the same marketed drugs as adults.
Few drugs are specifically indicated for use in children with severe hypertension.
Cardene I.V. has been widely used in children with severe hypertension without specific dosing recommendations for children in the labeling.
This study is designed to examine the pharmacokinetics, pharmacodynamics, safety, and efficacy of using Cardene I.V. to reduce blood pressure (BP) in children with hypertension and will provide important information to guide use in pediatric patients.
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90211
-
-
Florida
-
Miami, Florida, United States, 33145
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 16 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Evidence of Stage 1 or Stage 2 systolic hypertension at the time of screening.
- Male or female subjects, ages ≥2 to ≤16 years.
Females who meet either of the following criteria:
Non-childbearing potential , as documented by:
- a medical history of non-menstruation or
- surgical sterility from oophorectomy and/or hysterectomy. * A history of tubal ligation or evidence of a sterile sexual partner is insufficient evidence of non-childbearing potential.
- Childbearing potential: provide a negative urine pregnancy test within 24 hours of administration of study drug and agree to utilize effective contraception or remain abstinent during the entire treatment and follow-up periods of the study.
- Signed informed consent provided by an authorized subject representative and assent from subject, if feasible (based on local Institutional Review Board (IRB)/ethics panel requirements).
Exclusion Criteria:
- Subjects with seizures, altered state of consciousness, chest pain, facial palsy or intracranial hemorrhage at the time of screening.
- Receiving antihypertensive medication within a duration specified prior to screening.
- Treatment with cimetidine within 10 hours prior to dosing with study drug.
- Any known or suspected allergy to nicardipine hydrochloride.
- A calculated Glomerular Filtration Rate (GFR) under 30 mL/min/ 1.73 m2 as calculated using the Schwartz formula and the associated K values.
- Known history of severe aortic stenosis.
- Known history of severe left ventricular dysfunction.
- Known history of severely impaired hepatic function with portal hypertension.
- Liver function test (AST or ALT) results greater than or equal to twice the upper limit of normal.
- Receiving maintenance hemodialysis at screening or anticipated to require hemodialysis within 12 hours following initiation of treatment with study drug.
- Receiving a blood transfusion at screening or anticipated to require blood transfusions within 12 hours following initiation of treatment with study drug.
- Lack of appropriate intravenous (I.V.) access.
- Inability to tolerate a large-volume I.V. infusion.
- Any other condition or prior therapy, which, in the opinion of the investigator, would make the subject unsuitable for this study.
- Participation in any phase of another clinical research study involving the evaluation of another investigational drug or device within 30 days before randomization.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 1
|
|
Experimental: 2
5 mcg
|
|
Experimental: 3
2.5
|
|
Experimental: 4
0.5
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean percent change in SBP (Systolic Blood Pressure) from baseline during the 30-minute Randomized, Placebo-controlled Infusion Phase for each dose level of Cardene I.V. compared to placebo.
Time Frame: 30 minutes
|
30 minutes
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
1) Mean percent change in SBP and DBP between various phases of dosing. 2) Proportion of subjects requiring additional antihypertensive medications during the treatment period. 3) Mean effective dose of Cardene I.V.
Time Frame: 72
|
72
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2007
Primary Completion (Actual)
December 1, 2008
Study Completion (Actual)
December 1, 2008
Study Registration Dates
First Submitted
September 10, 2007
First Submitted That Met QC Criteria
September 11, 2007
First Posted (Estimate)
September 12, 2007
Study Record Updates
Last Update Posted (Estimate)
March 16, 2012
Last Update Submitted That Met QC Criteria
March 15, 2012
Last Verified
March 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Cardene® I.V. 1406
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
Clinical Trials on Cardene® I.V.
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationCompletedKidney Failure, AcuteSwitzerland, Italy
-
PfizerTerminated
-
University of MinnesotaMedical University of South Carolina; Johns Hopkins University; National Institute... and other collaboratorsTerminatedIntracerebral HemorrhageUnited States, Taiwan, Korea, Republic of, Germany, Japan, Canada, China
-
AbbVieBoehringer IngelheimCompletedPsoriasisUnited States, Germany, United Kingdom
-
Boehringer IngelheimCompleted
-
Savient PharmaceuticalsCompletedChronic Gout Refractory to Conventional TherapyUnited States
-
GC Biopharma CorpRecruitingHepatitis BKorea, Republic of
-
Boehringer IngelheimCompleted
-
Oslo University HospitalVestre VikenHF Kongsberg SykehusRecruitingOpioid Use | Affective SymptomsNorway
-
Novo Nordisk A/SCompletedHealthy | Diabetes Mellitus, Type 2 | DiabetesUnited Kingdom